Obesity-associated muscle atrophy poses a significant health challenge. Isoquercetin (IQ) exhibits potent anti-inflammatory, antioxidant, and metabolic regulatory effects; however, whether IQ can attenuate this condition remains elusive. Thus, we employed a mouse model of HFD-induced obesity-associated muscle atrophy to assess its therapeutic potential. Compared to the HFD vehicle group, IQ treatment enhanced grip strength (>45.5%, p 17.1%, p 34.5%, p p p IL-1β) and gut barrier permeability (1.66-fold lower of ZO-1), as well as reshaped gut microbial community and modulated bile acid composition in obese mice. Overall, these results provide novel evidence that IQ supplementation has the potential for mitigating obesity-related muscle atrophy.
Song et al. (Sun,) studied this question.